| __timestamp | Catalyst Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 612613000000 |
| Thursday, January 1, 2015 | 8597010 | 650773000000 |
| Friday, January 1, 2016 | 7910260 | 619061000000 |
| Sunday, January 1, 2017 | 7304399 | 628106000000 |
| Monday, January 1, 2018 | 15875961 | 717599000000 |
| Tuesday, January 1, 2019 | 36881187 | 964737000000 |
| Wednesday, January 1, 2020 | 44233754 | 875663000000 |
| Friday, January 1, 2021 | 49628000 | 886361000000 |
| Saturday, January 1, 2022 | 58183000 | 997309000000 |
| Sunday, January 1, 2023 | 133710000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Takeda Pharmaceutical Company Limited and Catalyst Pharmaceuticals, Inc. offer a fascinating study in contrasts. Over the past decade, Takeda's SG&A expenses have consistently hovered around the trillion-dollar mark, reflecting its expansive global operations. In contrast, Catalyst Pharmaceuticals has shown a more modest trajectory, with expenses peaking at approximately $134 million in 2023, a significant increase from $4.5 million in 2014.
While Takeda's expenses are nearly 10,000 times higher than Catalyst's, the latter's rapid growth in SG&A costs—nearly 30 times over the period—signals aggressive expansion. This data highlights the strategic choices each company makes in balancing growth and cost management. As the pharmaceutical landscape evolves, these insights provide a window into how industry leaders navigate financial challenges.
Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Catalyst Pharmaceuticals, Inc.
Walgreens Boots Alliance, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.